Posts

Risk adjusted net present value: What is the current va...

Epinephrine is a small molecule commercialized by Aquestive Therapeutics, with a...

Risk adjusted net present value: What is the current va...

JZP-898 is a fusion protein commercialized by Jazz Pharmaceuticals, with a leadi...

Risk adjusted net present value: What is the current va...

SGT-003 is a gene therapy commercialized by Solid Biosciences, with a leading Ph...

Risk adjusted net present value: What is the current va...

FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a lead...

Risk adjusted net present value: What is the current va...

TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading P...

Risk adjusted net present value: What is the current va...

CTX-131 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, w...

Carisma to undergo staff and clinical candidate restruc...

Carisma, a Philadelphia-based biotech company, is undergoing significant restruc...

BioAge Halts Phase 2 Obesity Study Just Two Months Afte...

BioAge Labs, a recent success in the biotechnology IPO market, has made a surpri...

Risk adjusted net present value: What is the current va...

Lemzoparlimab is a monoclonal antibody commercialized by I-Mab, with a leading P...

Risk adjusted net present value: What is the current va...

(Clesacostat tromethamine + Ervogastat) is a small molecule commercialized by Pf...

Risk adjusted net present value: What is the current va...

Imlunestrant tosylate is a small molecule commercialized by Eli Lilly and Co, wi...

Risk adjusted net present value: What is the current va...

ADI-001 is a gene-modified cell therapy commercialized by Adicet Bio, with a lea...

Risk adjusted net present value: What is the current va...

Rapcabtagene autoleucel is a gene-modified cell therapy commercialized by Novart...

Flu vaccine strategy on the line as new US leaders anti...

Public health experts are anticipating a changing discourse following RFK Jr’s a...

AIM ImmunoTech gains Netherlands patent for post-Covid ...

AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampli...

Risk adjusted net present value: What is the current va...

RLYB-116 is a fusion protein commercialized by Rallybio, with a leading Phase I ...